Erratum: Early events associated with infection of epstein-barr virus infection of primary b-cells (PLoS ONE (2009) 4:9 (e7214) DOI: 10.1371/journal.pone.0007214);Early events associated with infection of Epstein-Barr virus infection of primary B-cells

PLoS ONE

Volumn 4, Issue 9, 2009, Pages

  Halder, Sabyasachi ^a   Murakami, Masanao ^a   Verma, Subhash C ^a   Kumar, Pankaj ^a   Yi, Fuming ^a   Robertson, Erle S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD23 ANTIGEN; CD39 ANTIGEN; CD40 ANTIGEN; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; GREEN FLUORESCENT PROTEIN; HERMES ANTIGEN; KI 67 ANTIGEN; MEMBRANE ANTIGEN; PRIMER DNA;

ARTICLE; B LYMPHOCYTE; CELL GROWTH; CELL IMMORTALIZATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; GENE EXPRESSION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS INFECTION; BACTERIAL ARTIFICIAL CHROMOSOME; BIOLOGICAL MODEL; CELL LINE; CHEMISTRY; EPSTEIN BARR VIRUS INFECTION; METABOLISM; METHODOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY; VIRUS CELL TRANSFORMATION; VIRUS GENOME;

HUMAN HERPESVIRUS 4;

ANTIGENS, SURFACE; B-LYMPHOCYTES; CELL LINE; CELL TRANSFORMATION, VIRAL; CHROMOSOMES, ARTIFICIAL, BACTERIAL; DNA PRIMERS; EPSTEIN-BARR VIRUS INFECTIONS; FLOW CYTOMETRY; GENOME, VIRAL; GREEN FLUORESCENT PROTEINS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOCYTE ACTIVATION; MODELS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 70349694198     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0256674     Document Type: Erratum

References (80)

1. Thompson MP, Kurzrock R (2004) Epstein-Barr virus and cancer. Clin Cancer Res 10: 803-821.
2. Kobayashi I, Shima K, Saito I, Kiyoshima T, Matsuo K, et al. (1999) Prevalence of Epstein-Barr virus in oral squamous cell carcinoma. J Pathol 189: 34-39.
3. Sixbey JW, Davis DS, Young LS, Hutt-Fletcher L, Tedder TF, et al. (1987) Human epithelial cell expression of an Epstein-Barr virus receptor. J Gen Virol 68 (Pt3): 805-811.
4. Baumforth KR, Young LS, Flavell KJ, Constandinou C, Murray PG (1999) The Epstein-Barr virus and its association with human cancers. Mol Pathol 52: 307-322.
5. Jones JF, Shurin S, Abramowsky C, Tubbs RR, Sciotto CG, et al. (1988) T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med 318: 733-741.
6. Takada K (2001) Role of Epstein-Barr virus in Burkitt's lymphoma. Curr Top Microbiol Immunol 258: 141-151.
7. Rickinson AB, Kieff E (2001) Epstein-Barr virus. In: Howley DMK PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, eds. Fields virology 4th ed. Philadelphia: Lippincott Williams & Wilkins, Philadelphia, Pa. pp 2575-2627.
8. Tanner J, Weis J, Fearon D, Whang Y, Kieff E (1987) Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 50: 203-213.
9. Kuppers R (2003) B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 3: 801-812.
10. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, et al. (2004) Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci U S A 101: 239-244.
11. Kieff E, Rikinson AB (2001) Epstein-Barr virus and its replication. In: Howley DMK PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, eds. Fields virology 4th ed. Philadelphia: Lippincott Williams & Wilkins, Philadelphia, Pa. pp 2511-2573.
12. Cordier-Bussat M, Billaud M, Calender A, Lenoir GM (1993) Epstein-Barr virus (EBV) nuclear-antigen-2-induced up-regulation of CD21 and CD23 molecules is dependent on a permissive cellular context. Int J Cancer 53: 153-160.
13. Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, et al. (1990) Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 64: 2309-2318.
14. Kieff E (1996) Epstein-Barr virus and its replication. In: Howley DMK PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, eds. Fields virology 4th ed. Philadelphia: Lippincott Williams & Wilkins, Philadelphia, Pa. pp 2443-2396.
15. Kenney S, Kamine J, Holley-Guthrie E, Lin JC, Mar EC, et al. (1989) The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J Virol 63: 1729-1736.
16. Flemington E, Speck SH (1990) Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J Virol 64: 1227-1232.
17. Young LS, Murray PG (2003) Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22: 5108-5121.
18. Lin JC, Sista ND, Besencon F, Kamine J, Pagano JS (1991) Identification and functional characterization of Epstein-Barr virus DNA polymerase by in vitro transcription-translation of a cloned gene. J Virol 65: 2728-2731.
19. Wolf H, Bogedain C, Schwarzmann F (1993) Epstein-Barr virus and its interaction with the host. Intervirology 35: 26-39.
20. Ring CJ (1994) The B cell-immortalizing functions of Epstein-Barr virus. J Gen Virol 75 (Pt1): 1-13.
21. Post LE, Roizman B (1981) A generalized technique for deletion of specific genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential for growth. Cell 25: 227-232.
22. Mocarski ES, Post LE, Roizman B (1980) Molecular engineering of the herpes simplex virus genome: insertion of a second L-S junction into the genome causes additional genome inversions. Cell 22: 243-255.
23. Smiley JR (1980) Construction in vitro and rescue of a thymidine kinase-deficient deletion mutation of herpes simplex virus. Nature 285: 333-335.
24. Kempkes B, Pich D, Zeidler R, Hammerschmidt W (1995) Immortalization of human primary B lymphocytes in vitro with DNA. Proc Natl Acad Sci U S A 92: 5875-5879.
25. Tomkinson B, Robertson E, Kieff E (1993) Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 67: 2014-2025.
26. Kaye KM, Izumi KM, Kieff E (1993) Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A 90: 9150-9154.
27. Brune W, Messerle M, Koszinowski UH (2000) Forward with BACs: new tools for herpesvirus genomics. Trends Genet 16: 254-259.
28. Smith GA, Enquist LW (2000) A self-recombining bacterial artificial chromosome and its application for analysis of herpesvirus pathogenesis. Proc Natl Acad Sci U S A 97: 4873-4878.
29. Chen A, Divisconte M, Jiang X, Quink C, Wang F (2005) Epstein-Barr virus with the latent infection nuclear antigen 3B completely deleted is still competent for B-cell growth transformation in vitro. J Virol 79: 4506-4509.
30. Flemington E, Speck SH (1990) Epstein-Barr virus BZLF1 trans activator induces the promoter of a cellular cognate gene, c-fos. J Virol 64: 4549-4552.
31. Farrell PJ, Rowe DT, Rooney CM, Kouzarides T (1989) Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J 8: 127-132.
32. Pope JH, Horne MK, Scott W (1968) Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpeslike virus. Int J Cancer 3: 857-866.
33. Henle W, Diehl V, Kohn G, Zur Hausen H, Henle G (1967) Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science 157: 1064-1065.
34. Ross W, Hall PA (1995) Ki67: from antibody to molecule to understanding? Clin Mol Pathol 48: M113-M117.
35. Miller RA, Gralow J (1984) The induction of Leu-1 antigen expression in human malignant and normal B cells by phorbol myristic acetate (PMA). J Immunol 133: 3408-3414.
36. Gagro A, McCloskey N, Challa A, Holder M, Grafton G, et al. (2000) CD5-positive and CD5-negative human B cells converge to an indistinguishable population on signalling through B-cell receptors and CD40. Immunology 101: 201-209.
37. Kaplan D, Smith D, Meyerson H, Pecora N, Lewandowska K (2001) CD5 expression by B lymphocytes and its regulation upon Epstein-Barr virus transformation. Proc Natl Acad Sci U S A 98: 13850-13853.
38. Thorley-Lawson DA, Nadler LM, Bhan AK, Schooley RT (1985) BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus. J Immunol 134: 3007-3012.
39. Kintner C, Sugden B (1981) Identification of antigenic determinants unique to the surfaces of cells transformed by Epstein-Barr virus. Nature 294: 458-460.
40. Clark EA, Lane PJ (1991) Regulation of human B-cell activation and adhesion. Annu Rev Immunol 9: 97-127.
41. Kilger E, Kieser A, Baumann M, Hammerschmidt W (1998) Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 17: 1700-1709.
42. Klein E, Teramoto N, Gogolak P, Nagy N, Bjorkholm M (1999) LMP-1, the Epstein-Barr virus-encoded oncogene with a B cell activating mechanism similar to CD40. Immunol Lett 68: 147-154.
43. Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13-20.
44. Gerdes J, Dallenbach F, Lennert K, Lemke H, Stein H (1984) Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol 2: 365-371.
45. Pearson GR, Qualtiere LF (1978) Papain solubilization of the Epstein-Barr virus-induced membrane antigen. J Virol 28: 344-351.
46. Nemerow GR, Wolfert R, McNaughton ME, Cooper NR (1985) Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol 55: 347-351.
47. Herrold RE, Marchini A, Fruehling S, Longnecker R (1996) Glycoprotein 110, the Epstein-Barr virus homolog of herpes simplex virus glycoprotein B, is essential for Epstein-Barr virus replication in vivo. J Virol 70: 2049-2054.
48. Gong M, Ooka T, Matsuo T, Kieff E (1987) Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB. J Virol 61: 499-508.
49. Neuhierl B, Feederle R, Hammerschmidt W, Delecluse HJ (2002) Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. Proc Natl Acad Sci U S A 99: 15036-15041.
50. Schaeffer HJ, Beauchamp L, de Miranda P, Elion GB, Bauer DJ, et al. (1978) 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 272: 583-585.
51. Colby BM, Shaw JE, Elion GB, Pagano JS (1980) Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J Virol 34: 560-568.
52. Datta AK, Colby BM, Shaw JE, Pagano JS (1980) Acyclovir inhibition of Epstein-Barr virus replication. Proc Natl Acad Sci U S A 77: 5163-5166.
53. Speck P, Longnecker R (1999) Epstein-Barr virus (EBV) infection visualized by EGFP expression demonstrates dependence on known mediators of EBV entry. Arch Virol 144: 1123-1137.
54. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W (1998) Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci U S A 95: 8245-8250.
55. Kanda T, Yajima M, Ahsan N, Tanaka M, Takada K (2004) Production of high-titer Epstein-Barr virus recombinants derived from Akata cells by using a bacterial artificial chromosome system. J Virol 78: 7004-7015.
56. Chalfie M (1995) Green fluorescent protein. Photochem Photobiol 62: 651-656.
57. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC (1994) Green fluorescent protein as a marker for gene expression. Science 263: 802-805.
58. Lan K, Verma SC, Murakami M, Bajaj B, Robertson ES (2007) Epstein-Barr Virus (EBV): infection, propagation, quantitation, and storage. Curr Protoc Microbiol Chapter 14: Unit 14E 12.
59. Farrel PJ (2005) Epstein-Barr Virus Genome; Robertson ES, ed. Philadelphia: Caister Academic press.
60. Mann KP, Staunton D, Thorley-Lawson DA (1985) Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J Virol 55: 710-720.
61. Maunders MJ, Petti L, Rowe M (1994) Precipitation of the Epstein-Barr virus protein EBNA 2 by an EBNA 3c-specific monoclonal antibody. J Gen Virol 75 (Pt4): 769-778.
62. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
63. Verma SC, Lan K, Choudhuri T, Cotter MA, Robertson ES (2007) An autonomous replicating element within the KSHV genome. Cell Host Microbe 2: 106-118.
64. Brooks LA, Lear AL, Young LS, Rickinson AB (1993) Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J Virol 67: 3182-3190.
65. Calender A, Billaud M, Aubry JP, Banchereau J, Vuillaume M, et al. (1987) Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. Proc Natl Acad Sci U S A 84: 8060-8064.
66. Uckun FM, Jaszcz W, Ambrus JL, Fauci AS, Gajl-Peczalska K, et al. (1988) Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71: 13-29.
67. Nadler LM, Anderson KC, Marti G, Bates M, Park E, et al. (1983) B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 131: 244-250.
68. Bikah G, Carey J, Ciallella JR, Tarakhovsky A, Bondada S (1996) CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells. Science 274: 1906-1909.
69. Ishii Y, Mori M, Onoe T (1972) Studies on the germinal center. IV. Autoradiographic study of lymph node germinal centers in relation to zonal differentiation. J Reticuloendothel Soc 11: 383-393.
70. Wang D, Liebowitz D, Wang F, Gregory C, Rickinson A, et al. (1988) Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 62: 4173-4184.
71. van Kooten C, Banchereau J (1997) Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 9: 330-337.
72. Imadome K, Shirakata M, Shimizu N, Nonoyama S, Yamanashi Y (2003) CD40 ligand is a critical effector of Epstein-Barr virus in host cell survival and transformation. Proc Natl Acad Sci U S A 100: 7836-7840.
73. Imadome K, Shimizu N, Yajima M, Watanabe K, Nakamura H, et al. (2009) CD40 signaling activated by Epstein-Barr virus promotes cell survival and proliferation in gastric carcinoma-derived human epithelial cells. Microbes Infect 11: 429-433.
74. Kryworuckho M, Diaz-Mitoma F, Kumar A (1995) CD44 isoforms containing exons V6 and V7 are differentially expressed on mitogenically stimulated normal and Epstein-Barr virus-transformed human B cells. Immunology 86: 41-48.
75. Alfieri C, Birkenbach M, Kieff E (1991) Early events in Epstein-Barr virus infection of human B lymphocytes. Virology 181: 595-608.
76. Yuan J, Cahir-McFarland E, Zhao B, Kieff E (2006) Virus and cell RNAs expressed during Epstein-Barr virus replication. J Virol 80: 2548-2565.
77. Dalens M, Zech L, Klein G (1975) Origin of lymphoid lines established from mixed cultures of cord-blood lymphocytes and explants from infectious mononucleosis, Burkitt lymphoma and healthy donors. Int J Cancer 16: 1008-1014.
78. Rickinson AB, Jarvis JE, Crawford DH, Epstein MA (1974) Observations on the type of infection by Epstein-Barr virus in peripheral lymphoid cells of patients with infectious mononucleosis. Int J Cancer 14: 704-715.
79. Rickinson AB, Finerty S, Epstein MA (1977) Comparative studies on adult donor lymphocytes infected by EB virus in vivo or in vitro: origin of transformed cells arising in co-cultures with foetal lymphocytes. Int J Cancer 19: 775-782.
80. Lewin N, Aman P, Masucci MG, Klein E, Klein G, et al. (1987) Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth. Int J Cancer 39: 472-476.